Federal Cannabis Legalization: Policy Status, Reform Bills, and Timeline

Executive Summary

Federal cannabis legalization remains the most consequent unresolved policy question in American drug law, affecting 40+ states with legal programs, $30+ billion in annual sales, and millions of patients and consumers operating in legal-state markets while facing federal criminal liability. As of May 2026, cannabis remains a Schedule I controlled substance under the Controlled Substances Act (21 U.S.C. § 812), classified alongside heroin despite 38 states authorizing medical use and 24 permitting adult recreational sales. Recent calls from Representative Ilhan Omar and other federal lawmakers have intensified pressure for comprehensive reform, citing economic imperatives including tax revenue exceeding $15 billion annually in legal states, social justice concerns over 600,000+ annual arrests nationally, and the untenable federalism conflict where state-legal businesses cannot access banking, bankruptcy protection, or federal tax deductions under Internal Revenue Code Section 280E.

The path to federal legalization involves multiple potential mechanisms: congressional descheduling through legislation such as proposed versions of the Cannabis Administration and Opportunity Act, administrative rescheduling through the Drug Enforcement Administration and Department of Health and Human Services, or incremental reforms addressing banking (SAFE Banking Act) and taxation separately. Each approach carries distinct implications for interstate commerce, FDA regulation, existing state programs, and the $100+ billion illicit market that continues operating alongside legal channels.

Why Federal Cannabis Legalization Matters

Federal cannabis prohibition creates a unique legal paradox where state-authorized businesses operate in direct violation of federal law, generating systemic dysfunction across banking, taxation, research, criminal justice, and interstate commerce. The stakes span multiple constituencies with conflicting interests and enormous financial exposure.

For patients and consumers, federal prohibition means limited research into medical applications, inconsistent product safety standards across states, and potential federal prosecution despite state compliance. Approximately 5.8 million registered medical cannabis patients nationwide face uncertainty when traveling across state lines or seeking federal employment. Veterans receiving care through the Department of Veterans Affairs cannot receive cannabis recommendations from VA physicians despite state legalization, forcing them into private markets.

For businesses and investors, the conflict costs billions annually. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, resulting in effective tax rates exceeding 70% for cannabis operators. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings collectively paid an estimated $1.8 billion in additional federal taxes in 2025 due to 280E restrictions. Banking access remains severely limited, with fewer than 700 of 4,800+ federally insured institutions willing to service cannabis clients according to FinCEN reports, forcing many dispensaries to operate cash-intensive businesses vulnerable to theft and complicating regulatory compliance.

For state and local governments, federal prohibition undermines regulatory frameworks and tax collection while creating public safety challenges. States collected $15.2 billion in cannabis tax revenue in 2025, funding education, infrastructure, and drug treatment programs, yet federal illegality prevents interstate commerce that could reduce prices and improve supply chain efficiency. Local law enforcement faces conflicting mandates, with federal agencies occasionally intervening in state-legal operations.

For criminal justice and social equity, continued federal prohibition perpetuates enforcement disparities. Despite similar usage rates across demographics, Black Americans are 3.64 times more likely to be arrested for cannabis possession according to ACLU data. Federal convictions, though relatively rare compared to state charges, carry mandatory minimums and immigration consequences including deportation for non-citizens. An estimated 40,000 individuals remain incarcerated in federal facilities for cannabis offenses, with tens of thousands more on supervised release.

Background and History: The Path to Federal Prohibition

Cannabis prohibition at the federal level emerged through a century-long process of racialized enforcement, international treaty obligations, and expanding federal drug control authority that culminated in the 1970 Controlled Substances Act.

Early Regulation and the Marihuana Tax Act (1906-1937)

Cannabis appeared in the United States Pharmacopeia from 1850 through 1942 as a recognized medicine. The Pure Food and Drug Act of 1906 required labeling of cannabis content but did not prohibit sales. State-level prohibition began in 1913 when California restricted cannabis sales, followed by Texas in 1919 and numerous other states through the 1920s and 1930s, often driven by anti-Mexican immigrant sentiment and claims linking cannabis to violence.

The Marihuana Tax Act of 1937 established the first federal restrictions, imposing registration requirements and prohibitive taxes on cannabis transactions rather than outright criminalization. Federal Bureau of Narcotics Commissioner Harry Anslinger led the campaign for the Act, testifying before Congress with claims that cannabis caused insanity and violence, disproportionately targeting Mexican and Black communities in enforcement rhetoric. The Act remained in effect until the Supreme Court struck it down in Leary v. United States (1969) on Fifth Amendment self-incrimination grounds.

The Controlled Substances Act and Schedule I Classification (1970)

President Richard Nixon signed the Comprehensive Drug Abuse Prevention and Control Act on October 27, 1970, establishing the modern framework under Title II, the Controlled Substances Act. The Act created five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I, defined as substances with high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision.

The classification was intended as temporary. The Act established the National Commission on Marihuana and Drug Abuse (the Shafer Commission) to study cannabis and recommend policy. In 1972, the Commission recommended decriminalizing possession of small amounts for personal use, concluding that cannabis did not meet Schedule I criteria. Nixon rejected the recommendation, and cannabis remained Schedule I. The Drug Enforcement Administration, created in 1973, assumed enforcement authority.

Escalation and Mandatory Minimums (1980s-1990s)

The Reagan administration dramatically expanded enforcement. The Anti-Drug Abuse Act of 1986 established mandatory minimum sentences for drug offenses, including federal cannabis cultivation and distribution. The Act created a 100-to-1 sentencing disparity between crack and powder cocaine that disproportionately affected Black defendants, setting a precedent for harsh drug sentencing that extended to cannabis cases. Federal cannabis arrests increased from approximately 5,000 annually in 1980 to over 60,000 by 1995.

The 1990s saw continued escalation. The Violent Crime Control and Law Enforcement Act of 1994 expanded federal death penalty eligibility to include large-scale drug trafficking. Asset forfeiture programs allowed federal agencies to seize property connected to drug offenses, creating financial incentives for cannabis enforcement. By 2000, approximately 45,000 individuals were incarcerated in federal prisons for drug offenses, with cannabis accounting for roughly 15% of federal drug prisoners.

State Medical Cannabis and Federal Conflict (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, becoming the first state to legalize medical cannabis. The Clinton administration responded with threats to revoke DEA registrations of physicians recommending cannabis. In Conant v. Walters (2002), the Ninth Circuit Court of Appeals ruled that physicians have a First Amendment right to recommend cannabis, but federal prohibition remained intact.

The Supreme Court reinforced federal authority in Gonzales v. Raich (2005), holding that the Commerce Clause empowers Congress to prohibit locally grown cannabis even for personal medical use authorized by state law. Justice Stevens wrote for the 6-3 majority that homegrown cannabis could substantially affect interstate commerce in the aggregate, upholding CSA application to state-legal activity. The decision confirmed that state legalization does not provide immunity from federal prosecution.

Despite Raich, the Bush and Obama administrations adopted policies of limited federal enforcement in states with robust medical cannabis regulations. Deputy Attorney General James Cole issued a memorandum on August 29, 2013 (the "Cole Memo") establishing enforcement priorities focused on preventing distribution to minors, revenue to criminal enterprises, and diversion to prohibition states, effectively deprioritizing prosecution of state-compliant operators.

Adult-Use Legalization and Federal Response (2012-2020)

Colorado and Washington voters approved adult-use legalization on November 6, 2012, with sales beginning in 2014. The Obama administration extended Cole Memo principles to adult-use programs. By 2016, California, Massachusetts, Maine, and Nevada had joined, creating a legal market exceeding $6 billion in annual sales.

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, restoring full prosecutorial discretion to U.S. Attorneys. However, few federal prosecutions of state-compliant operators followed, partly due to congressional appropriations riders (the Rohrabacher-Farr amendment, later Rohrabacher-Blumenauer) prohibiting DOJ from using funds to prevent states from implementing medical cannabis laws. The rider has been renewed in every appropriations bill since 2014 but does not protect adult-use programs or individual defendants.

Recent Reform Momentum (2020-Present)

The House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act on December 4, 2020, by a vote of 228-164, marking the first time either chamber approved federal descheduling. The bill would have removed cannabis from the CSA, imposed a 5% federal sales tax, and established expungement procedures. The Senate did not advance the legislation. The House passed an updated MORE Act again on April 1, 2022, by 220-204, but again the Senate declined to act.

President Biden issued pardons on October 6, 2022, for all federal simple possession offenses, affecting approximately 6,500 individuals with federal convictions and thousands more with D.C. offenses. Biden simultaneously directed HHS and DOJ to review cannabis scheduling. On August 30, 2023, HHS recommended rescheduling cannabis to Schedule III, acknowledging accepted medical use. The DEA initiated a rescheduling proceeding, publishing a Notice of Proposed Rulemaking on May 21, 2024, with a comment period extending through July 22, 2024. As of May 2026, the DEA has not issued a final rule, and cannabis remains Schedule I.

Key Players in the Federal Legalization Debate

Federal cannabis policy involves executive agencies, congressional leaders, industry stakeholders, advocacy organizations, and opposition groups with billions of dollars and millions of lives in the balance.

Drug Enforcement Administration

The DEA holds statutory authority to schedule controlled substances under 21 U.S.C. § 811, subject to HHS medical and scientific evaluation. DEA Administrator Anne Milgram oversees the pending rescheduling proceeding. Historically, the DEA has opposed liberalization, denying multiple rescheduling petitions between 1972 and 2016. Administrative Law Judge Francis Young recommended rescheduling in 1988, finding cannabis "one of the safest therapeutically active substances known to man," but DEA Administrator John Lawn rejected the recommendation. The current rescheduling proceeding represents the first time the agency has formally proposed moving cannabis from Schedule I, though to Schedule III rather than full descheduling.

Department of Health and Human Services and FDA

HHS conducts medical and scientific evaluations for scheduling decisions. The Food and Drug Administration, within HHS, would assume regulatory authority over cannabis as a drug or food ingredient upon descheduling or rescheduling. FDA has approved four cannabis-derived or synthetic cannabinoid drugs: Epidiolex (cannabidiol for seizures), Marinol and Syndros (synthetic THC for nausea and appetite), and Cesamet (synthetic cannabinoid nabilone). FDA Commissioner Robert Califf has indicated the agency would require significant resources to regulate a descheduled cannabis market, potentially treating products as either drugs requiring approval or supplements subject to different standards.

Congressional Leaders and Legislation

Senate Majority Leader Chuck Schumer, along with Senators Cory Booker and Ron Wyden, introduced the Cannabis Administration and Opportunity Act on July 21, 2021, proposing comprehensive descheduling, federal taxation at 10-25% ramping over five years, and social equity provisions. The bill has not advanced to a floor vote. Representative Nancy Mace introduced the States Reform Act on November 15, 2021, offering a more limited federal framework preserving state authority. Representative Earl Blumenauer and Senator Ron Wyden have championed incremental reforms including the SAFE Banking Act, which has passed the House seven times but stalled in the Senate.

Representative Ilhan Omar's May 14, 2026 call for comprehensive reform emphasized economic benefits including job creation exceeding 400,000 positions in legal cannabis and ancillary industries, and social justice imperatives to address enforcement disparities. Omar specifically cited tax revenue potential and the need to expunge federal cannabis convictions, joining a growing caucus of over 100 House members supporting full legalization.

Multi-State Operators and Industry Groups

Publicly traded MSOs including Curaleaf Holdings, Green Thumb Industries, Trulieve Cannabis, Cresco Labs, and Verano Holdings operate hundreds of dispensaries across dozens of states, collectively generating over $10 billion in annual revenue while unable to list on major U.S. stock exchanges due to federal prohibition. These companies trade on Canadian exchanges or over-the-counter markets with limited liquidity. The Cannabis Trade Federation, National Cannabis Industry Association, and U.S. Cannabis Council lobby for federal reform, prioritizing banking access and 280E relief even absent full descheduling.

Advocacy and Social Equity Organizations

The Drug Policy Alliance, Marijuana Policy Project, and NORML have advocated for legalization for decades, emphasizing criminal justice reform and medical access. The Last Prisoner Project focuses on clemency and expungement for cannabis prisoners. Social equity advocates including the Minority Cannabis Business Association emphasize that legalization must include restorative justice, expungement, and business opportunities for communities disproportionately harmed by prohibition. These groups have criticized incremental reforms that benefit large operators without addressing past harms.

Opposition: Law Enforcement and Prevention Groups

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposes legalization, citing public health concerns including youth use, impaired driving, and cannabis use disorder. The group advocates for decriminalization without commercialization. Some law enforcement organizations, including the National Sheriffs' Association, have opposed legalization, citing concerns about drugged driving and cartel activity, though other law enforcement groups including Law Enforcement Action Partnership support legalization as a harm reduction measure. The Community Anti-Drug Coalitions of America opposes commercialization, emphasizing prevention.

Legal and Regulatory Framework

Federal cannabis prohibition rests on the Controlled Substances Act, international treaty obligations, and a complex web of ancillary statutes affecting taxation, banking, immigration, and federal benefits.

Controlled Substances Act Scheduling Criteria

Under 21 U.S.C. § 812, Schedule I substances must meet three criteria: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Schedule III substances, where HHS has recommended moving cannabis, have accepted medical use, moderate to low potential for physical dependence, and less abuse potential than Schedule I or II. Rescheduling to Schedule III would maintain cannabis as a controlled substance subject to DEA regulation but would eliminate 280E tax penalties and potentially ease research restrictions. Full descheduling would remove cannabis from the CSA entirely, eliminating federal criminal penalties and DEA oversight.

Criminal Penalties Under Current Law

Federal cannabis offenses carry severe penalties. Manufacturing or distributing 1,000 kilograms or more, or 1,000 or more plants, carries a 10-year mandatory minimum and up to life imprisonment under 21 U.S.C. § 841(b)(1)(A). Amounts of 100 kilograms or 100 plants trigger a 5-year mandatory minimum. Simple possession of any amount is a misdemeanor for first offense, carrying up to one year imprisonment and a $1,000 fine under 21 U.S.C. § 844. Subsequent offenses escalate to felonies. Conspiracy to distribute, under 21 U.S.C. § 846, carries the same penalties as the underlying offense.

Internal Revenue Code Section 280E

Section 280E, enacted in 1982 following a Tax Court case involving a cocaine trafficker, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses including rent, payroll, and marketing, though cost of goods sold remains deductible. The provision applies regardless of state legality. A cannabis dispensary with $10 million in revenue, $6 million in cost of goods sold, and $3 million in operating expenses would pay federal tax on $4 million rather than $1 million, resulting in effective tax rates of 60-80%. Rescheduling to Schedule III would eliminate 280E application; full descheduling would allow normal business deductions.

Banking and Financial Services

The Bank Secrecy Act (31 U.S.C. § 5318) requires financial institutions to report suspicious activity. FinCEN issued guidance in 2014 establishing that banks may service cannabis businesses in compliance with state law if they file Suspicious Activity Reports and conduct due diligence, but most banks decline due to federal illegality and regulatory burden. The SAFE Banking Act would create a safe harbor protecting financial institutions from federal penalties for serving state-legal cannabis businesses. The legislation has passed the House multiple times but stalled in the Senate over demands to include social equity provisions and expungement.

International Treaty Obligations

The United States is party to three international drug control treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs. The Single Convention requires parties to limit cannabis to medical and scientific use. Some legal scholars argue that federal descheduling would violate treaty obligations, though Canada and Uruguay have legalized cannabis while remaining treaty parties by interpreting obligations as requiring good-faith efforts rather than absolute prohibition. The U.S. could withdraw from treaties, renegotiate, or adopt similar interpretive approaches.

State-by-State Legal Status

As of May 2026, 38 states and four territories have legalized medical cannabis, while 24 states and two territories permit adult recreational use, creating a patchwork of regulations that federal legalization would dramatically reshape.

Adult-Use Legal States

California legalized adult use through Proposition 64 on November 8, 2016, with sales beginning January 1, 2018. Adults 21+ may possess up to one ounce and cultivate six plants. The state imposes a 15% excise tax and local taxes reaching 10% in some jurisdictions. California generated $1.1 billion in cannabis tax revenue in 2025, though illicit market sales continue to exceed legal sales due to high taxes and regulatory costs.

Colorado became the first state with legal adult-use sales on January 1, 2014, following voter approval of Amendment 64 in November 2012. Adults may possess up to one ounce and cultivate six plants, with three flowering. The state collected $468 million in cannabis taxes in 2025. Colorado's regulatory framework has served as a model for subsequent states, with seed-to-sale tracking and local control over licensing.

New York legalized adult use through the Marijuana Regulation and Taxation Act, signed March 31, 2021, with retail sales beginning December 29, 2022. Adults may possess up to three ounces and cultivate three mature and three immature plants. New York's social equity program prioritizes licenses for individuals with prior cannabis convictions and residents of communities with high enforcement rates. The state projects $1.25 billion in annual tax revenue at market maturity.

Illinois launched adult-use sales January 1, 2020, following legislative approval. The Cannabis Regulation and Tax Act includes expungement provisions that have cleared over 500,000 records. Illinois collected $445 million in cannabis taxes in 2025. The state reserves 20% of licenses for social equity applicants.

Other adult-use states include Alaska, Arizona, Connecticut, Delaware, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, Ohio, Oregon, Rhode Island, Vermont, Virginia, and Washington, plus the District of Columbia and Guam. Possession limits typically range from one to 2.5 ounces, with home cultivation permitted in most but not all states.

Medical-Only States

Florida operates one of the nation's largest medical programs with over 850,000 registered patients as of 2026. Amendment 2, approved November 2016, authorized medical use for qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's, and multiple sclerosis. Smokable flower became available in 2019 following legislative action. Florida does not permit home cultivation. Trulieve dominates the market with over 180 dispensaries statewide.

Pennsylvania launched medical sales in February 2018 under the Medical Marijuana Act. The program serves over 450,000 patients with qualifying conditions including chronic pain, anxiety disorders, and opioid use disorder. Pennsylvania does not permit home cultivation or smokable flower, though vaporization is allowed.

Ohio voters approved adult-use legalization through Issue 2 on November 7, 2023, with implementation ongoing as of May 2026. The state's existing medical program, operational since 2019, serves approximately 200,000 patients.

Other medical-only states include Alabama, Arkansas, Hawaii, Louisiana, Mississippi, Missouri, Montana, New Hampshire, North Dakota, Oklahoma, South Dakota, Utah, and West Virginia, plus Puerto Rico and the U.S. Virgin Islands. Qualifying conditions and possession limits vary significantly.

Prohibition States

As of May 2026, twelve states maintain full prohibition with no legal medical or adult-use programs: Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Nebraska, North Carolina, South Carolina, Tennessee, Texas, Wisconsin, and Wyoming. Some have decriminalized possession of small amounts as civil infractions, while others maintain criminal penalties including potential incarceration. Federal legalization would not automatically override state prohibition, as states retain authority to maintain stricter laws, similar to alcohol policy where some counties remain dry.

Market and Business Implications of Federal Legalization

Federal legalization would fundamentally restructure a $30+ billion legal market and $60+ billion illicit market, enabling interstate commerce, institutional investment, and operational efficiencies while potentially disrupting existing state-licensed operators.

Interstate Commerce and Market Consolidation

Current state-by-state licensing prohibits interstate commerce, requiring MSOs to build redundant cultivation and processing facilities in each state. Federal legalization enabling interstate commerce would allow operators to consolidate production in states with lowest costs—likely outdoor cultivation states such as California, Oregon, and Oklahoma—and ship nationally. Wholesale cannabis prices would likely converge toward $200-400 per pound, compared to current ranges of $800-2,000 depending on state. Small operators in high-cost states would face severe pressure, while large MSOs with capital to build interstate distribution would gain market share.

Banking, Capital Markets, and Investment

Federal legalization would enable cannabis companies to list on NYSE and NASDAQ, access conventional banking, and attract institutional investment currently restricted by federal illegality. Analysts project major alcohol and tobacco companies would acquire leading MSOs, with transaction values potentially exceeding $50 billion for top operators. Altria, Constellation Brands, and Molson Coors have made strategic investments in cannabis companies anticipating federal reform. Credit card processors including Visa and Mastercard would enable cashless transactions, reducing theft and improving compliance. Bankruptcy protection under federal law would become available, allowing restructuring rather than liquidation for struggling operators.

Taxation and Revenue

Proposed federal legalization bills typically include excise taxes ranging from 5-25% at wholesale or retail level. A 10% federal excise tax on a $30 billion market would generate $3 billion annually, in addition to existing state and local taxes. Elimination of 280E would reduce effective tax rates for operators, improving profitability and potentially enabling price reductions. However, combined federal, state, and local taxes exceeding 30-40% could perpetuate illicit markets, as seen in California where high taxes contribute to continued unlicensed sales.

Impact on Multi-State Operators

Leading MSOs have positioned for federal reform through multi-state licensing, vertical integration, and brand development. Curaleaf Holdings operates 151 dispensaries across 19 states with $1.4 billion in 2025 revenue. Green Thumb Industries operates 77 stores across 15 states with $1.0 billion in revenue. Trulieve Cannabis dominates Florida with 184 locations and generated $1.2 billion in revenue. Federal reform would enable these operators to access lower-cost capital, eliminate 280E penalties saving hundreds of millions annually, and potentially expand through acquisition. However, interstate commerce could commoditize products, compressing margins and favoring low-cost producers over premium brands.

Pharmaceutical and CBD Markets

FDA regulation of cannabis as a drug or supplement would create pathways for pharmaceutical development while potentially restricting existing products. The agency could require clinical trials and approval processes for medical claims, disadvantaging dispensary products marketed for therapeutic use. The CBD market, estimated at $5 billion annually, operates in legal gray area following the 2018 Farm Bill's hemp legalization; federal cannabis legalization would clarify CBD's status but might subject products to stricter regulation. Major pharmaceutical companies including Jazz Pharmaceuticals and GW Pharmaceuticals (acquired by Jazz) have invested in cannabinoid drug development, potentially competing with dispensary channels.

What Experts and Stakeholders Say

Policy experts, industry leaders, and advocates offer divergent perspectives on federal legalization's timing, structure, and consequences.

According to the Drug Policy Alliance, comprehensive legalization must prioritize restorative justice over commercial interests. The organization has stated that reform should include automatic expungement of all federal cannabis convictions, resentencing for individuals currently incarcerated, and reinvestment of tax revenue in communities disproportionately harmed by enforcement. The group opposes incremental measures such as SAFE Banking without accompanying social equity provisions.

The National Cannabis Industry Association supports a federalist approach preserving state regulatory authority while eliminating federal prohibition. The trade group has emphasized that operators need banking access and 280E relief immediately, even if full descheduling takes years. According to the association, over 70% of cannabis businesses lack adequate banking relationships, creating public safety risks and compliance challenges.

Smart Approaches to Marijuana maintains that legalization has failed to eliminate illicit markets and has increased youth access and cannabis use disorder rates. The organization points to data from Colorado showing youth past-month use rates of 14% compared to 12% nationally, and emergency department visits involving cannabis increasing 54% from 2016 to 2020. The group advocates for decriminalization of possession without commercial legalization.

According to researchers at the RAND Corporation, federal legalization's impact depends critically on tax rates and regulatory structure. The think tank's modeling suggests that taxes below 15% combined with interstate commerce could reduce retail prices by 50-75%, dramatically expanding the legal market but potentially increasing consumption and cannabis use disorder prevalence. RAND has recommended that policymakers prioritize public health outcomes over revenue maximization.

Former FDA Commissioner Scott Gottlieb has stated that the agency lacks resources to regulate a descheduled cannabis market effectively. According to Gottlieb, FDA would need significant additional funding and statutory authority to establish product standards, testing requirements, and marketing restrictions comparable to tobacco regulation. Without adequate FDA oversight, product quality and safety could remain inconsistent.

Senator Cory Booker has emphasized that legalization without restorative justice would perpetuate existing inequities. According to Booker, any federal reform must include expungement, community reinvestment, and barriers to corporate consolidation that would exclude small and minority-owned businesses. Booker has blocked incremental banking legislation lacking these provisions.

What's Next: Timeline and Scenarios

Federal cannabis legalization could occur through multiple pathways over the next 12-36 months, with administrative rescheduling, congressional legislation, or continued state-level expansion as competing scenarios.

DEA Rescheduling Decision (2026)

The DEA's proposed rescheduling to Schedule III remains pending as of May 14, 2026, following the July 2024 comment period that generated over 43,000 submissions. The agency must review comments, conduct an administrative hearing if requested by objectors, and issue a final rule. Legal challenges are certain regardless of outcome. If the DEA finalizes Schedule III rescheduling, effective date would likely be 60-90 days after publication in the Federal Register, potentially by late 2026. This would eliminate 280E penalties and ease research restrictions but maintain federal criminal penalties for unauthorized possession and distribution.

Congressional Legislation (2027-2028)

Comprehensive descheduling legislation faces uncertain prospects. Senate passage requires 60 votes to overcome filibuster, necessitating Republican support unlikely in current political environment. However, incremental measures including SAFE Banking and modest tax reform could advance if packaged with unrelated priorities. The 2026 midterm elections could shift Senate composition, potentially enabling passage in 2027. Presidential election dynamics in 2028 may create momentum if candidates compete on cannabis reform. Most analysts project congressional descheduling as unlikely before 2028 absent significant political realignment.

State Expansion and Ballot Initiatives

Florida voters will likely consider adult-use legalization in November 2026, with polling showing 64% support. Approval would create the nation's largest adult-use market, potentially exceeding $6 billion annually and increasing pressure for federal action. Additional states including Pennsylvania, Ohio (implementation of existing authorization), and potentially Texas (medical only) may expand programs in 2026-2027. By 2028, analysts project 30+ states with adult-use legalization representing 75% of U.S. population, making federal prohibition increasingly untenable.

Scenario Planning for Operators

Cannabis businesses face strategic decisions with multi-year implications. Operators expanding multi-state footprints assume federal reform enabling interstate commerce within 3-5 years, requiring capital expenditure of $50-200 million per state for cultivation and processing. Single-state operators focusing on brand development and retail experience bet on maintaining local advantages even after federal reform. Ancillary businesses including software, testing, and real estate have positioned for growth regardless of federal timeline. Investors must weigh current cash flow against uncertain reform timing, with public MSO valuations implying market expectation of federal reform by 2028.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 21, 2024) — https://www.federalregister.gov/documents/2024/05/21/2024-11137/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS Recommendation to Reschedule Cannabis (August 2023) — https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (Updated 2024) — https://crsreports.congress.gov/product/pdf/R/R44782
• ACLU, "A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform" (2020) — https://www.aclu.org/report/tale-two-countries

  Update — May 25, 2026: Federal-State Cannabis Legal Divide Persists

  As of May 2026, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, despite legalization in a majority of U.S. states for medical or adult-use purposes. The Winston-Salem Journal highlighted the ongoing legal ambiguity, noting that federal prohibition continues to create conflicts with state-level regulatory frameworks across banking, taxation, and interstate commerce. No federal rescheduling or descheduling action has been finalized by the Drug Enforcement Administration or Congress as of this date.

  The article underscored that state-licensed cannabis operators remain subject to federal prosecution, though enforcement priorities have varied across presidential administrations. Financial institutions continue to cite the Bank Secrecy Act and anti-money laundering regulations as barriers to serving cannabis businesses, forcing many operators to conduct transactions in cash. IRS Code Section 280E prohibits standard business deductions for entities trafficking in Schedule I substances, imposing effective tax rates exceeding 70 percent on compliant state-legal businesses.

  Legal experts quoted in the report emphasized that no congressional cannabis reform bill has advanced to a floor vote in either chamber during the current legislative session. Prior efforts including the Marijuana Opportunity Reinvestment and Expungement Act and the SAFE Banking Act have stalled in committee or failed to secure sufficient bipartisan support. The lack of federal clarity continues to complicate interstate expansion, intellectual property protections, and access to capital markets for publicly traded cannabis companies.

  The persistent federal-state conflict affects patient access in states where medical cannabis is legal but federal programs such as Veterans Affairs healthcare prohibit physician recommendations. Federal employees and contractors remain subject to drug-free workplace policies that treat cannabis use as grounds for termination, regardless of state law. This regulatory patchwork creates operational risk for multi-state operators and limits the ability of researchers to conduct FDA-approved clinical trials under current DEA licensing requirements.

  Update — May 25, 2026: Federal-State Cannabis Legality Paradox Persists

  As of May 2026, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, despite operational legal markets in 38 states for medical use and 24 states for adult recreational use. The Longview Daily News highlighted the ongoing jurisdictional conflict, noting that state-licensed operators face continued barriers to interstate commerce, federal banking access, and IRS Section 280E tax treatment that disallows standard business deductions.

  No comprehensive federal legalization bill has advanced to a floor vote in the 119th Congress, according to congressional tracking databases. The Cannabis Administration and Opportunity Act, reintroduced in modified form in January 2026, remains in the Senate Finance Committee without a markup schedule. Federal enforcement policy continues under the rescinded Cole Memorandum framework, leaving prosecutorial discretion to individual U.S. Attorneys' offices.

  The legal ambiguity affects over 15,000 state-licensed cannabis businesses that operate in compliance with state law but remain vulnerable to federal asset forfeiture and criminal liability. Industry stakeholders said the lack of federal clarity constrains access to capital markets, with most operators relying on private equity and debt financing at interest rates 8-12 percentage points above conventional small business loans.

  This matters because the federal-state conflict imposes operational costs estimated at $1.8 billion annually across the regulated industry, according to a March 2026 analysis by the National Cannabis Industry Association. Until Congress enacts descheduling or rescheduling legislation, state-legal operators will continue navigating contradictory legal frameworks that limit growth, banking relationships, and investor confidence.

  Update — May 25, 2026: Federal-State Cannabis Legal Divide Persists

  As of mid-2026, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, creating an ongoing conflict with state-level legalization programs now operating in 38 states for medical use and 24 states for adult recreational use. The Daily Progress reported that this "kind of, sort of" legal status continues to create operational challenges for licensed businesses, which cannot access traditional banking services or claim standard federal tax deductions under Internal Revenue Code Section 280E.

  Federal enforcement policy has relied on prosecutorial discretion since the rescission of the Cole Memorandum in 2018, leaving state-legal operators vulnerable to federal intervention despite low practical enforcement risk. Interstate commerce in cannabis remains prohibited, forcing each state market to operate as a closed loop and preventing economies of scale that would benefit multi-state operators. Banking access remains limited to approximately 700 financial institutions willing to file Suspicious Activity Reports for cannabis clients, according to FinCEN data through Q1 2026.

  The SAFER Banking Act, which passed the Senate in 2024 but stalled in House-Senate conference, has not been reintroduced in the current congressional session. No comprehensive federal legalization bill has advanced past committee hearings since the MORE Act in 2022. Industry advocates have shifted focus to administrative rescheduling through the Drug Enforcement Administration's ongoing review process, initiated in August 2023 following a Department of Health and Human Services recommendation to move cannabis to Schedule III.

  The legal ambiguity affects an estimated $33.6 billion annual legal cannabis market according to industry data, with operators paying effective federal tax rates exceeding 70 percent due to 280E restrictions. Patient access programs in medical-only states face particular uncertainty, as federal prohibition prevents physicians at VA hospitals and other federal facilities from recommending cannabis despite state authorization.

  Update — May 25, 2026: Federal-State Legal Divergence Persists Amid Stalled Reform

  As of May 2026, cannabis remains a Schedule I controlled substance under the federal Controlled Substances Act, creating ongoing legal uncertainty despite widespread state-level legalization. The Omaha World-Herald highlighted the continued federal prohibition even as 38 states have enacted medical cannabis programs and 24 states permit adult-use sales, according to the National Conference of State Legislatures.

  Federal banking restrictions under the Bank Secrecy Act continue to force most cannabis operators to conduct business largely in cash, exposing them to security risks and limiting access to traditional financial services. The SAFE Banking Act, which would shield financial institutions serving state-legal cannabis businesses from federal penalties, has passed the House seven times since 2019 but remains stalled in the Senate with no floor vote scheduled.

  The Department of Justice maintains its enforcement discretion policy, prioritizing prosecutions involving interstate trafficking, sales to minors, and cartel activity while generally declining to prosecute state-compliant operators. However, this policy offers no statutory protection and can be reversed by any administration without congressional action. Federal employees, including military personnel and civil servants, face termination for cannabis use regardless of state law.

  Industry analysts estimate the legal cannabis market generated $33.6 billion in sales during 2025, yet operators cannot deduct ordinary business expenses under Internal Revenue Code Section 280E, which prohibits deductions for businesses trafficking in Schedule I or II substances. This tax treatment results in effective federal tax rates often exceeding 70 percent for dispensaries and cultivators, according to the Cannabis Trade Federation.

  Update — May 25, 2026: Federal-State Cannabis Legality Gap Persists

  Cannabis remains illegal under federal law in the United States despite 38 states having legalized medical marijuana and 24 states having legalized adult-use sales as of May 2026, according to Fredericksburg.com. The Controlled Substances Act continues to classify cannabis as a Schedule I drug, creating ongoing conflicts between state-licensed operators and federal enforcement agencies including the DEA and FBI.

  State-legal cannabis businesses cannot access traditional banking services or federal bankruptcy protections due to the federal prohibition, forcing many operators to conduct transactions in cash. The Internal Revenue Code Section 280E prohibits these businesses from deducting ordinary business expenses on federal tax returns, resulting in effective tax rates exceeding 70 percent for some dispensaries and cultivation facilities.

  Federal rescheduling efforts have stalled in Congress throughout 2026, with no floor votes scheduled on the Cannabis Administration and Opportunity Act or the SAFE Banking Act. The Department of Justice maintains prosecutorial discretion over state-legal operators, though enforcement priorities have shifted away from compliant medical and recreational programs since the 2013 Cole Memorandum framework.

  This legal ambiguity affects approximately 428,000 workers employed in state-licensed cannabis operations nationwide, who remain technically vulnerable to federal prosecution despite state compliance. Investors in multi-state operators face restrictions on listing shares on major U.S. stock exchanges, with most cannabis companies trading on Canadian exchanges or over-the-counter markets.

  The contradiction between state legalization and federal prohibition continues to complicate interstate commerce, product testing standards, and medical research access. Federal research permits for cannabis studies require DEA approval, limiting clinical trials to a single federally approved cultivation facility at the University of Mississippi until alternative suppliers receive authorization.